Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Trastuzumab

Show all topics

DOI

10.1016/s1470-2045(11)70336-9